Tazarotene

TAZORAC

What it isTopical retinoid and RAR agonist; plaque psoriasis and acne.

Why this oneUnlike adapalene or tretinoin, it carries both acne and plaque-psoriasis indications.

What limits itIrritation commonly limits use, and retinoid teratogenicity makes pregnancy a contraindication.

FDA-approved for

FDA dosing	Population	Start	Target	Max
Plaque psoriasis	Adults & peds ≥12 yr	0.05% gel QHS	increase to 0.1% if tolerated	≤20% BSA
Acne vulgaris	Adults & peds ≥12 yr	0.1% gel QHS	0.1% QHS

Renal Undefined

Hepatic Undefined

Topical only; thin layer to affected area in the evening, wash hands after
Not for ophthalmic, oral, or intravaginal use; rinse with water if contact with mucous membranes/eyes
Apply to dry skin; if emollients used, apply ≥1 hr before gel
Use daily sunscreen and protective clothing
Not for eczematous skin

Embryofetal toxicity: negative pregnancy test within 2 wk before start and effective contraception during use
Local irritation (pruritus, burning, erythema, peeling) — reduce frequency or concentration; do not use on eczematous skin
Photosensitivity / sunburn risk; caution with other photosensitizers

Psoriasis: pruritus, burning/stinging, erythema, worsening psoriasis, irritation, skin pain
Acne: desquamation, burning/stinging, dry skin, erythema, pruritus

Pregnancy Contraindicated — may cause fetal harm (retinoid teratogen); discontinue if pregnancy recognized

Lactation No human data; consider benefits vs mother's need (present in rat milk)

NO BOXED WARNINGS

Principal riskIrritation; teratogenic

Cost, est. cash$10–$300/month

Generic entry2017

Therapeutic safety burden0 / 4

Overdose danger0 / 4

Weight-gain liability0 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk3 / 4

Legacy pregnancy categoryX

Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.